Ingenia Therapeutics Closed Venture Round
Cambridge-based Ingenia Therapeutics, a biotechnology company developing a therapeutic antibody candidate for capillary diseases recently closed a $7 million venture capital round, per an SEC filing. Terms of the round were not disclosed. Company will use this funding to accelerate business growth. Ingenia is a privately held biotechnology company specializing in the discovery and development … Read more